You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

49 Results
Guidelines and Advice
Status: Current
ID: GL 8-11
Jan 2018
Guidelines and Advice
Status: Current
Version: 1
Mar 2018
Guidelines and Advice
Status: Current
ID: GL 21-2v2
Version: 2
Nov 2018
Guidelines and Advice
Status: Current
ID: N/A
Version: 1
Mar 2018
Guidelines and Advice
Status: Archived
ID: GL 11-12
Apr 2018
Guidelines and Advice
Status: Current
ID: PET 2017-2
Version: n/a
May 2018
Guidelines and Advice
Status: Current
ID: pet 2018-1
Version: n/a
Oct 2018
Guidelines and Advice
Status: Current
ID: ES SMG-2
Jun 2018
Guidelines and Advice
Status: Current
ID: PET 19
Version: n/a
Nov 2018
Regimen
Cancer Type:
Genitourinary, 
Prostate
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
  • niLUTAmide
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
niLUTAmide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2018
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Eribulin - Metastatic or Incurable Locally Advanced - Breast Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
eriBULin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jan 2018
Guidelines and Advice
Status: Current
ID: GL-C50-06
Jan 2018

Pages